ARHGAP21 prevents abnormal insulin release through actin rearrangement in pancreatic islets from neonatal mice

Life Sciences
Sandra Mara FerreiraHelena Cristina Barbosa-Sampaio

Abstract

ARHGAP21 is a Rho GTPase-activating protein (RhoGAP) that associates with many proteins and modulates several cellular functions, including actin cytoskeleton rearrangement in different tissues. However, it is unknown whether ARHGAP21 is expressed in pancreatic beta cells and its function in these cells. Herein, we assess the participation of ARHGAP21 in insulin secretion. Neonatal mice were treated with anti-sense oligonucleotide against ARHG AP21 (AS) for 2 days, resulting in a reduction of the protein's expression of about 60% in the islets. F-actin depolimerization, insulin secretion,mRNA level of genes involved in insulin secretion, maturation and proliferation were evaluated in islets from both control and AS-treated mice. ARHGAP21 co-localized with actin inMIN6 beta cells and with insulin in neonatal pancreatic islets. F-actin was reduced in AS-islets, as judged by lower phalloidin intensity. Insulin secretion was increased in islets from AS-treated mice, however no differences were observed in the GSIS (glucose-stimulated insulin secretion). In these islets, the pERK1/2 was increased, as well as the gene expressions of VAMP2 and SNAP25, proteins that are present in the secretory machinery. Maturation and cell proliferat...Continue Reading

References

Jan 1, 1986·Diabetes/metabolism Reviews·M D Meglasson, F M Matschinsky
Jun 26, 2001·Diabetes/metabolism Research and Reviews·S Del Prato, A Tiengo
Jun 12, 2002·Biochemical and Biophysical Research Communications·Daniela Sanchez BassèresSara Teresinha Olalla Saad
May 23, 2003·American Journal of Physiology. Cell Physiology·Angela K Nevins, Debbie C Thurmond
Jul 24, 2004·American Journal of Physiology. Endocrinology and Metabolism·Lorna M Dickson, Christopher J Rhodes
May 23, 2006·The Journal of Biological Chemistry·Angela K Nevins, Debbie C Thurmond
Mar 10, 2007·The EMBO Journal·Julie MénétreyAnne Houdusse
Feb 21, 2008·The Journal of Biological Chemistry·Jenna L JewellDebbie C Thurmond
Jul 30, 2008·Biochemical and Biophysical Research Communications·Luciene BorgesSara Teresinha Olalla Saad
Mar 10, 2009·Biochimica Et Biophysica Acta·Carolina Louzão BigarellaSara Terezinha Olalla Saad
Aug 21, 2009·Molecular Biology of the Cell·Heidi HehnlyMark Stamnes
Jun 8, 2010·Traffic·Heidi HehnlyMark Stamnes
Aug 11, 2011·American Journal of Physiology. Endocrinology and Metabolism·Erica M KepnerDebbie C Thurmond
Sep 1, 2011·Diabetes Research and Clinical Practice·Jean-Claude Henquin
Dec 6, 2011·The Journal of Biological Chemistry·Dieter RondasPhilippe A Halban
Dec 4, 2012·Biochimica Et Biophysica Acta·Mariana LazariniSara T Olalla Saad
Aug 24, 2013·Experimental & Molecular Medicine·Michael A Kalwat, Debbie C Thurmond

❮ Previous
Next ❯

Citations

Jun 2, 2018·Journal of Cellular Physiology·Lucas R O RosaHelena C L Barbosa-Sampaio
Jun 28, 2019·Canadian Journal of Physiology and Pharmacology·Lucas ZangerolamoHelena Cristina Barbosa-Sampaio
Mar 27, 2018·Journal of Cellular Physiology·Gabriela M SoaresHelena C Barbosa-Sampaio

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antidiabetic Cellular Plasticity

This feed focuses on mechanisms that underlie cellular plasticity as a treatment for diabetes and other degenerative diseases.

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.